Management of Chronic Hypertension with Superimposed Preeclampsia
Women with chronic hypertension who develop superimposed preeclampsia require immediate hospital assessment, aggressive blood pressure control targeting diastolic BP of 85 mmHg, magnesium sulfate for seizure prophylaxis if severe features are present, and delivery at 37 weeks or earlier if maternal or fetal complications develop. 1
Blood Pressure Management
Severe Hypertension (≥160/110 mmHg)
- Requires urgent treatment in a monitored setting 1
- First-line agents:
- Oral nifedipine (preferred)
- IV labetalol
- IV hydralazine
- Oral labetalol may be used if IV agents unavailable 1
Non-Severe Hypertension (≥140/90 mmHg)
- Initiate or titrate antihypertensive therapy at BP ≥140/90 mmHg 1
- Target diastolic BP: 85 mmHg (systolic 110-140 mmHg) 1
- This approach reduces risk of severe hypertension and complications like thrombocytopenia and elevated liver enzymes 1
- Acceptable oral agents:
- Methyldopa
- Labetalol
- Nifedipine
- Oxprenolol
- Second/third-line: hydralazine, prazosin 1
- Reduce or cease antihypertensives if diastolic BP falls <80 mmHg 1
Critical caveat: The CHIPS trial demonstrated that tight BP control (targeting diastolic 85 mmHg) reduces severe hypertension without compromising fetal outcomes, contradicting older approaches that avoided treatment of non-severe hypertension 1.
Magnesium Sulfate for Seizure Prophylaxis
Administer MgSO₄ if the patient has:
- Proteinuria AND severe hypertension (≥160/110 mmHg), OR
- Neurological signs/symptoms (severe headache, visual disturbances, clonus) 1
Dosing Regimen
- Loading dose: 4g IV or 10g IM 1
- Maintenance: 5g IM every 4 hours OR 1g/hour IV infusion 1
- Duration: Continue until delivery and for 24 hours postpartum 1
- Use dosing regimens from the Eclampsia and MAGPIE trials 1
Maternal Monitoring Protocol
Clinical Assessment
- BP monitoring: At least every 4-6 hours 1
- Neurological status: Assess for headache, visual symptoms, clonus 1
- Proteinuria: Repeat assessments if not already present 1
Laboratory Testing
Twice weekly minimum (more frequently with clinical changes): 1
- Complete blood count (hemoglobin, platelets)
- Liver transaminases (AST, ALT)
- Serum creatinine
- Uric acid
Important: Neither uric acid level nor degree of proteinuria should determine timing of delivery 1
Fetal Monitoring
- Initial assessment: Fetal biometry, amniotic fluid volume, umbilical artery Doppler 1
- If initial assessment normal: Repeat every 2 weeks 1
- If fetal growth restriction present: More frequent amniotic fluid and Doppler assessments 1
Delivery Timing and Indications
Gestational Age-Based Approach
≥37 weeks: Deliver immediately 1
34-37 weeks: Expectant conservative management with close monitoring 1
<34 weeks: Conservative management at center with Maternal-Fetal Medicine expertise 1
Immediate Delivery Indications (Regardless of Gestational Age)
Deliver immediately if ANY of the following develop: 1
Maternal indications:
- Repeated severe hypertension despite 3 classes of antihypertensives at appropriate doses
- Progressive thrombocytopenia
- Progressively abnormal liver or renal function tests
- Pulmonary edema
- Severe intractable headache
- Repeated visual scotomata
- Eclampsia (seizures)
- Maternal oxygen saturation <90% 1
Fetal indications:
- Non-reassuring fetal status
- Reversed end-diastolic flow on umbilical artery Doppler
- Placental abruption
- Stillbirth 1
Critical point: Do not attempt to classify as "mild" versus "severe" preeclampsia—all cases can become emergencies rapidly 1
Intrapartum Management
- Continue oral antihypertensives at start of labor 1
- Fluid restriction: Limit total intake to 60-80 mL/hour to prevent pulmonary edema 1
- Aim for euvolemia (30 mL/h for insensible losses + 0.5-1 mL/kg/h anticipated urinary output)
- Do not "run dry"—these patients are already at risk for acute kidney injury 1
- IV antihypertensives may be needed if GI motility is reduced 1
Postpartum Management
Immediate Postpartum (First 3-5 Days)
- BP monitoring: Every 4-6 hours for at least 3 days 1
- Continue MgSO₄ for 24 hours postpartum 1
- Monitor for eclampsia: Can occur postpartum 1
- Laboratory monitoring: Repeat CBC, platelets, creatinine, liver enzymes day after delivery, then every other day until stable 1
Antihypertensive Management
- Restart antihypertensives after delivery 1
- Taper slowly only after days 3-6 postpartum unless BP becomes low (<110/70 mmHg) or patient symptomatic 1
- Avoid NSAIDs if possible, especially with acute kidney injury—use alternative analgesia 1
Discharge Planning
- Most women can be discharged by day 5 postpartum, especially with home BP monitoring capability 1
Follow-Up
Short-Term (Within 1 Week)
- Review within 1 week if still requiring antihypertensives at discharge 1
3-Month Postpartum Visit
- All women must be reviewed at 3 months postpartum 1
- By this time, BP, urinalysis, and all laboratory tests should have normalized
- If abnormalities persist: Work up for secondary causes of hypertension or underlying renal disease 1
- Screen for depression, anxiety, posttraumatic stress disorder 1
Long-Term
- Lifelong cardiovascular follow-up required 1
- These women have increased lifetime risk of cardiovascular disease, stroke, diabetes, venous thromboembolism, and chronic kidney disease 1
Key Clinical Pitfalls to Avoid
Do not withhold antihypertensive treatment for non-severe hypertension (≥140/90 mmHg)—this increases risk of progression to severe hypertension and complications 1
Do not use uric acid or proteinuria levels to determine delivery timing 1
Do not attempt expectant management if any immediate delivery indication is present 1
Do not fluid overload—maintain euvolemia with 60-80 mL/hour to prevent pulmonary edema 1
Do not discharge early postpartum without ensuring adequate BP control and follow-up plan—up to 44% of pregnancy-related deaths occur in first 6 days postpartum 2
Do not use plasma volume expansion routinely 1